Concordance in biomarker status between bladder tumors at time of transurethral resection and subsequent radical cystectomy: Results of a 5-year prospective study

Niccolò M. Passoni, Shahrokh F. Shariat, Aditya Bagrodia, Franto Francis, Varun Rachakonda, Evanguelos Xylinas, Payal Kapur, Arthur I Sagalowsky, Yair Lotan

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose: To assess the concordance rate in alterations of molecular markers at the time of transurethral resection (TUR) and subsequent radical cystectomy (RC) among patients with high-grade urothelial carcinoma of the bladder (UCB). Methods: We prospectively performed immunohistochemical staining p53, p21, p27, Ki-67 and cyclin E1 on TUR and on RC specimens from 102 patients treated with RC and bilateral lymphadenectomy for high-grade UCB.We analyzed the concordance rate of individual markers and of the number of altered markers. Concordant and discordant findings were reported in the overall population and according to clinical stage. Results: Median patient age was 74 years (IQR 67-79) and mostly male (86%). Median time from TUR to RC was 1.5 months (IQR 1.0-2.4). Clinical stage at time of RC was cTa/Tis/T1 in 50%, cT2 in 47%, and cT4 in 1% of patients Nine (9%) patients received neoadjuvant chemotherapy. The concordance of biomarkers between TUR and RC specimens was 92.2%, 77.5%, 80.4%, 77.5%, and 83.3% for cyclin E1, p21, p27, p53 and Ki-67, respectively. The concordance between number of altered biomarkers was 51.0%. Conclusions: The rate of individual marker alterations at time of TUR closely approximates that found at RC specimens. However, the correlation of number of altered markers is lower. Molecular marker status at TUR could help predict the marker status at RC and may help guide multimodal therapeutic planning.

Original languageEnglish (US)
Pages (from-to)91-99
Number of pages9
JournalBladder Cancer
Volume2
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

Cystectomy
Urinary Bladder Neoplasms
Biomarkers
Prospective Studies
Cyclins
Urinary Bladder
Carcinoma
Lymph Node Excision
Staining and Labeling
Drug Therapy
Population

Keywords

  • Bladder cancer
  • Cystectomy
  • Molecular markers
  • Transurethral resection of bladder tumors

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Concordance in biomarker status between bladder tumors at time of transurethral resection and subsequent radical cystectomy : Results of a 5-year prospective study. / Passoni, Niccolò M.; Shariat, Shahrokh F.; Bagrodia, Aditya; Francis, Franto; Rachakonda, Varun; Xylinas, Evanguelos; Kapur, Payal; Sagalowsky, Arthur I; Lotan, Yair.

In: Bladder Cancer, Vol. 2, No. 1, 01.01.2016, p. 91-99.

Research output: Contribution to journalArticle

@article{d19af0e4f176419c8fc89aed22f75780,
title = "Concordance in biomarker status between bladder tumors at time of transurethral resection and subsequent radical cystectomy: Results of a 5-year prospective study",
abstract = "Purpose: To assess the concordance rate in alterations of molecular markers at the time of transurethral resection (TUR) and subsequent radical cystectomy (RC) among patients with high-grade urothelial carcinoma of the bladder (UCB). Methods: We prospectively performed immunohistochemical staining p53, p21, p27, Ki-67 and cyclin E1 on TUR and on RC specimens from 102 patients treated with RC and bilateral lymphadenectomy for high-grade UCB.We analyzed the concordance rate of individual markers and of the number of altered markers. Concordant and discordant findings were reported in the overall population and according to clinical stage. Results: Median patient age was 74 years (IQR 67-79) and mostly male (86{\%}). Median time from TUR to RC was 1.5 months (IQR 1.0-2.4). Clinical stage at time of RC was cTa/Tis/T1 in 50{\%}, cT2 in 47{\%}, and cT4 in 1{\%} of patients Nine (9{\%}) patients received neoadjuvant chemotherapy. The concordance of biomarkers between TUR and RC specimens was 92.2{\%}, 77.5{\%}, 80.4{\%}, 77.5{\%}, and 83.3{\%} for cyclin E1, p21, p27, p53 and Ki-67, respectively. The concordance between number of altered biomarkers was 51.0{\%}. Conclusions: The rate of individual marker alterations at time of TUR closely approximates that found at RC specimens. However, the correlation of number of altered markers is lower. Molecular marker status at TUR could help predict the marker status at RC and may help guide multimodal therapeutic planning.",
keywords = "Bladder cancer, Cystectomy, Molecular markers, Transurethral resection of bladder tumors",
author = "Passoni, {Niccol{\`o} M.} and Shariat, {Shahrokh F.} and Aditya Bagrodia and Franto Francis and Varun Rachakonda and Evanguelos Xylinas and Payal Kapur and Sagalowsky, {Arthur I} and Yair Lotan",
year = "2016",
month = "1",
day = "1",
doi = "10.3233/BLC-150036",
language = "English (US)",
volume = "2",
pages = "91--99",
journal = "Bladder Cancer",
issn = "2352-3727",
publisher = "IOS Press",
number = "1",

}

TY - JOUR

T1 - Concordance in biomarker status between bladder tumors at time of transurethral resection and subsequent radical cystectomy

T2 - Results of a 5-year prospective study

AU - Passoni, Niccolò M.

AU - Shariat, Shahrokh F.

AU - Bagrodia, Aditya

AU - Francis, Franto

AU - Rachakonda, Varun

AU - Xylinas, Evanguelos

AU - Kapur, Payal

AU - Sagalowsky, Arthur I

AU - Lotan, Yair

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Purpose: To assess the concordance rate in alterations of molecular markers at the time of transurethral resection (TUR) and subsequent radical cystectomy (RC) among patients with high-grade urothelial carcinoma of the bladder (UCB). Methods: We prospectively performed immunohistochemical staining p53, p21, p27, Ki-67 and cyclin E1 on TUR and on RC specimens from 102 patients treated with RC and bilateral lymphadenectomy for high-grade UCB.We analyzed the concordance rate of individual markers and of the number of altered markers. Concordant and discordant findings were reported in the overall population and according to clinical stage. Results: Median patient age was 74 years (IQR 67-79) and mostly male (86%). Median time from TUR to RC was 1.5 months (IQR 1.0-2.4). Clinical stage at time of RC was cTa/Tis/T1 in 50%, cT2 in 47%, and cT4 in 1% of patients Nine (9%) patients received neoadjuvant chemotherapy. The concordance of biomarkers between TUR and RC specimens was 92.2%, 77.5%, 80.4%, 77.5%, and 83.3% for cyclin E1, p21, p27, p53 and Ki-67, respectively. The concordance between number of altered biomarkers was 51.0%. Conclusions: The rate of individual marker alterations at time of TUR closely approximates that found at RC specimens. However, the correlation of number of altered markers is lower. Molecular marker status at TUR could help predict the marker status at RC and may help guide multimodal therapeutic planning.

AB - Purpose: To assess the concordance rate in alterations of molecular markers at the time of transurethral resection (TUR) and subsequent radical cystectomy (RC) among patients with high-grade urothelial carcinoma of the bladder (UCB). Methods: We prospectively performed immunohistochemical staining p53, p21, p27, Ki-67 and cyclin E1 on TUR and on RC specimens from 102 patients treated with RC and bilateral lymphadenectomy for high-grade UCB.We analyzed the concordance rate of individual markers and of the number of altered markers. Concordant and discordant findings were reported in the overall population and according to clinical stage. Results: Median patient age was 74 years (IQR 67-79) and mostly male (86%). Median time from TUR to RC was 1.5 months (IQR 1.0-2.4). Clinical stage at time of RC was cTa/Tis/T1 in 50%, cT2 in 47%, and cT4 in 1% of patients Nine (9%) patients received neoadjuvant chemotherapy. The concordance of biomarkers between TUR and RC specimens was 92.2%, 77.5%, 80.4%, 77.5%, and 83.3% for cyclin E1, p21, p27, p53 and Ki-67, respectively. The concordance between number of altered biomarkers was 51.0%. Conclusions: The rate of individual marker alterations at time of TUR closely approximates that found at RC specimens. However, the correlation of number of altered markers is lower. Molecular marker status at TUR could help predict the marker status at RC and may help guide multimodal therapeutic planning.

KW - Bladder cancer

KW - Cystectomy

KW - Molecular markers

KW - Transurethral resection of bladder tumors

UR - http://www.scopus.com/inward/record.url?scp=85002704838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85002704838&partnerID=8YFLogxK

U2 - 10.3233/BLC-150036

DO - 10.3233/BLC-150036

M3 - Article

C2 - 27376130

AN - SCOPUS:85002704838

VL - 2

SP - 91

EP - 99

JO - Bladder Cancer

JF - Bladder Cancer

SN - 2352-3727

IS - 1

ER -